Developer docs
API playgroundTry for free, no card

Search company profiles

Vision X

Full company profile

uuid000a94j

Namestring
Vision X
Legal namestring
维视艾康特(广东)医疗科技股份有限公司
Websiteurl
icomfit.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Vision X (维视艾康特) is a Shanghai-headquartered, venture-backed Chinese ophthalmic medical device company founded in 2018 by Li Xiaowei (formerly of Alcon and Essilor Optics) and Fu Xiaoyang (former founder of medical device CRO Zhutong). The company develops, manufactures, and commercializes a vertically integrated portfolio of NMPA Class III ophthalmic devices and care products organized across five segments: myopia management (Ortho-K lenses, H.O.R.I. defocus spectacle lenses, silicone hydrogel multifocal soft lenses), irregular astigmatism and ocular surface health (scleral lenses — China's first domestically developed — and RGP lenses), ophthalmic diagnostic instruments (optical biometer with big-data analytics), lens care solutions (preservative-free sterile saline, multi-purpose rigid contact lens care solution), and soft contact lenses under the Mu Guang Li (沐光里) brand. Proprietary technology pillars include the H.O.R.I. (Hexagon Optimized Reticular Integration) grid-array optimization technology for myopia control, a four-zone scleral lens architecture with independently adjustable zones, ACT design for Ortho-K lenses, and an AI-powered fitting engine claiming ≥95% accuracy on corneal-topography-driven parameter ordering.

The company makes money primarily through one-time hardware sales of medical devices (Ortho-K, scleral, RGP lenses, spectacle lenses, diagnostic instruments) to hospitals and clinics, with growing repeat-purchase revenue from consumable care solutions (sterile saline, multi-purpose care solution) and soft contact lenses. Go-to-market combines direct enterprise field sales targeting top-tier ophthalmology hospitals for clinical validation and commercial supply (including KOL partnerships with Wenzhou Medical University Eye Hospital, Fudan University Eye Hospital, Tianjin Eye Hospital, and Peking University People's Hospital) with a nationwide distributor/dealer network for broader hospital and clinic penetration. Pricing is not publicly disclosed and is quoted case-by-case through sales representatives and distributors.

Vision X is registered as 维视艾康特(广东)医疗科技股份有限公司 (Guangdong) and operates manufacturing facilities across Shanghai (rigid lenses, headquarters), Hangzhou (diagnostic instruments), Ningbo, and Zhuhai (ocular care solutions), supported by wholly owned operating subsidiaries in each city. The company has raised multiple funding rounds from Angel through Series B+ (cumulative funding described in sources as 'exceeding 100 million RMB,' achieving unicorn status post-Series A), with investors including Sequoia Capital China (Series A lead), Sherpa Healthcare Partners, Fosun Venture Capital, Pine Venture Capital, YuanSheng Investment, Hengqin Financial Investment, and — per Crunchbase — Temasek and Lake Bleu Capital as cross-over participants. In 2023 it was designated a Shanghai Key Service Unicorn Potential Enterprise by the Shanghai Municipal Government and was named among the Top 10 Medical Device Investment Cases by Touzhong.com and the Top 50 Healthcare Investment Value Companies by CHC Medical.

Short descriptiontext

Vision X (维视艾康特) is a Shanghai-based Chinese medical device company that develops, manufactures, and sells NMPA Class III ophthalmic products — including Ortho-K lenses, domestically developed scleral lenses, myopia control spectacle lenses, optical biometers, and care solutions — serving hospitals, eye clinics, and patients across China.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersZhuhai, China
HQ citystring
Zhuhai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic medical devices, myopia control solutions, rigid contact lenses, orthokeratology lenses, ocular diagnostic equipment
Industry3 codes
PRIMARYHLAHAJAE
Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAHAJAD
Optical Dispensing & Eyewear Devices (Frames, Lenses, Lens Edging/Finishing Equipment)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAA
Comprehensive Eye Exams & Vision Care
NAICS code1 code
  • Ophthalmic Goods Manufacturing339115
SIC code1 code
  • Ophthalmic Goods3851
Product category
Ophthalmic Medical Devices
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Device Sales — Myopia Control Solutions
TypeHardware Sales
Description

Revenue from sale of myopia control products including orthokeratology lenses and related care solutions. One-time purchase model with repeat purchase of consumables/care products.

2Medical Device Sales — Ophthalmic Equipment
TypeHardware Sales
Description

Revenue from sale of ophthalmic diagnostic and treatment equipment to hospitals and clinics.

3Medical Device Sales — Ocular Surface Management
TypeHardware Sales
Description

Revenue from scleral lenses and ocular surface disease management devices for irregular cornea and dry eye patients.

Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1艾康菲 (iComfit)
Description

硬性巩膜接触镜、角膜塑形镜、RGP等核心接触镜产品品牌

+4 more records
Core offering1 text field

Vision X (维视艾康特) designs, manufactures, and sells ophthalmic medical devices and eye care solutions, including orthokeratology (Ortho-K) lenses, rigid gas permeable (RGP) scleral lenses, defocus spectacle lenses for myopia control, silicone hydrogel soft contact lenses, lens care solutions, and optical biometric diagnostic equipment. The company serves hospitals, eye clinics, and medical institutions in China through direct enterprise sales and a nationwide distributor network.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Vision X (维视艾康特) offers a comprehensive portfolio of ophthalmic medical devices and eye care solutions organized into five business segments: (1) Myopia Management - including 艾康菲®角膜塑形镜 (Ortho-K lenses with AI fitting), 艾沐皓锐®离焦框架镜 (H.O.R.I. spectacle lenses), and 硅水凝胶多焦软镜; (2) Irregular Astigmatism and Ocular Surface Health - including 艾康菲®硬性巩膜接触镜 (scleral lenses, first domestically developed) and 艾康菲®硬性角膜接触镜 (RGP lenses); (3) Ophthalmic Diagnostic Instruments - including 微晓远山®眼科光学生物测量仪 with big data analytics; (4) Lens Care Solutions - including 艾康舒®无菌生理盐水 and 洗眼液; and (5) Soft Contact Lenses - including 硅水凝胶单焦软镜 and 多焦软镜 under the 沐光里 brand. The company operates as a total vision care solutions provider, from front-end diagnostic equipment through vision correction products to care solutions.

Product and service5 records
1iComfit® Rigid Scleral Contact Lenses (艾康菲®硬性巩膜接触镜)
CategoryScleral Contact Lenses
Description

Class III rigid gas permeable scleral lens with four-zone design for correcting irregular corneal astigmatism and high refractive errors in patients with keratoconus, post-LASIK ectasia, and corneal scarring. Sold to ophthalmology hospitals and clinics.

2iComfit® Ortho-K Lenses (艾康菲®角膜塑形镜)
CategoryOrthokeratology Lenses
Description

Night-wear orthokeratology contact lenses that temporarily reshape the cornea to correct myopia, indicated for myopia up to -4.00D and astigmatism up to 1.50D. Features ACT design, SWET technology, and AI-powered corneal topography fitting for myopia control in pediatric and adolescent populations. Sold to eye hospitals and clinics.

3H.O.R.I. Myopia Control Spectacle Lenses (艾沐皓锐®离焦框架镜)
CategoryMyopia Control Spectacle Lenses
Description

Defocus spectacle lenses for myopia control in children and teenagers, using H.O.R.I. (Hexagon Optimized Reticular Integration) technology with a 67% filling ratio grid design featuring integrated mesh, fractal boundary, and full symmetry. Sold through eye hospitals, optometry clinics, and optical retailers.

4iComfit® RGP Contact Lenses (艾康菲®硬性角膜接触镜)
CategoryRigid Gas Permeable Contact Lenses
Description

Daily-wear rigid gas permeable contact lenses for correcting myopia and hyperopia, featuring smooth edge design, high oxygen permeability, and improved corneal fit. Sold to ophthalmology clinics and eye hospitals.

5Wei Xiao Yuan Shan® Optical Biometer (微晓远山®眼科光学生物测量仪)
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading ophthalmology hospital and clinical trial partner for Vision X's myopia control and scleral lens products. Provides clinical validation, KOL engagement, and academic credibility.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Top-tier eye hospital affiliated with Fudan University serving as a key clinical trial site and academic partner for Vision X's orthokeratology and ophthalmic device development.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Major ophthalmology hospital in northern China collaborating with Vision X on clinical research and product development for specialized eye care solutions.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Leading teaching hospital providing clinical research collaboration and academic endorsement for Vision X's ophthalmic products and technologies.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global ophthalmic medical device and contact lens leader (Precision1, Dailies, Air Optix) and Vision X founder Li Xiaowei's prior employer. Operates broadly across the same ophthalmic device categories but at a global scale; sets the competitive benchmark for premium contact lens, surgical, and vision care products in China.

TypeBroad incumbent
Description

Global contact lens, lens care, and ophthalmic pharmaceutical company with established presence across soft contact lenses, RGP, and lens care solutions in China. Directly competes with Vision X across multiple product lines including the iComsuit® care solution franchise.

TypeBroad incumbent
Description

World leader in disposable soft contact lenses (Acuvue franchise) and ortho-K (Acuvue Abiliti). Competes with Vision X in soft contact lenses, multifocal correction and myopia management categories in China.

TypeDirect peer
Description

US-based pioneer of Ortho-K lens designs for myopia control, with established distribution in China through partnerships. Competes directly with Vision X's iComfit® Ortho-K Lenses for hospital channel adoption and clinical trial validation sites.

TypeDirect peer
Description

Japan-based leader in RGP and specialty contact lenses (including ortho-K and scleral designs), with direct presence in China. Closely comparable to Vision X in scleral lens technology depth and Ortho-K offerings, and a potential international expansion benchmark.

TypeEmerging player
Description

Emerging Chinese player in ortho-K and defocus spectacle lenses, focused on the pediatric myopia control segment. Comparable to Vision X in scale and product overlap, and a direct domestic competitor for hospital channel partnerships.

TypeBroad incumbent
Description

Global contact lens manufacturer (clariti, Biofinity, MiSight myopia control lens). MiSight 1 day is a direct competitor to Vision X's pediatric myopia management soft lens strategy in China.

TypeDirect peer
Description

Manufacturer of specialty contact lenses including CRT (Corneal Refractive Therapy) ortho-K designs and gas permeable lenses. Competes with Vision X across both Ortho-K and RGP lens categories, particularly in markets where its CRT brand has been licensed to Chinese partners.

TypeDirect peer
Description

China's largest domestic orthokeratology (Ortho-K) lens manufacturer and a direct competitor to Vision X in the myopia control lens segment. Both companies target the same Chinese hospital and optometry clinic channels with prescription myopia management lenses and have overlapping clinical validation strategies with leading ophthalmology hospitals.

10Lucid Korea
TypeRegional player
Description

South Korea-based manufacturer of Ortho-K lenses with growing presence in Asia. Comparable to Vision X's Ortho-K technology focus and serves as a regional benchmark for scleral lens and Ortho-K product strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vision X

Ophthalmic Medical Devicesicomfit.com

Vision X (维视艾康特) is a Shanghai-based Chinese medical device company that develops, manufactures, and sells NMPA Class III ophthalmic products — including Ortho-K lenses, domestically developed scleral lenses, myopia control spectacle lenses, optical biometers, and care solutions — serving hospitals, eye clinics, and patients across China.

What Vision X does

Vision X (维视艾康特) is a Shanghai-headquartered, venture-backed Chinese ophthalmic medical device company founded in 2018 by Li Xiaowei (formerly of Alcon and Essilor Optics) and Fu Xiaoyang (former founder of medical device CRO Zhutong). The company develops, manufactures, and commercializes a vertically integrated portfolio of NMPA Class III ophthalmic devices and care products organized across five segments: myopia management (Ortho-K lenses, H.O.R.I. defocus spectacle lenses, silicone hydrogel multifocal soft lenses), irregular astigmatism and ocular surface health (scleral lenses — China's first domestically developed — and RGP lenses), ophthalmic diagnostic instruments (optical biometer with big-data analytics), lens care solutions (preservative-free sterile saline, multi-purpose rigid contact lens care solution), and soft contact lenses under the Mu Guang Li (沐光里) brand. Proprietary technology pillars include the H.O.R.I. (Hexagon Optimized Reticular Integration) grid-array optimization technology for myopia control, a four-zone scleral lens architecture with independently adjustable zones, ACT design for Ortho-K lenses, and an AI-powered fitting engine claiming ≥95% accuracy on corneal-topography-driven parameter ordering.

The company makes money primarily through one-time hardware sales of medical devices (Ortho-K, scleral, RGP lenses, spectacle lenses, diagnostic instruments) to hospitals and clinics, with growing repeat-purchase revenue from consumable care solutions (sterile saline, multi-purpose care solution) and soft contact lenses. Go-to-market combines direct enterprise field sales targeting top-tier ophthalmology hospitals for clinical validation and commercial supply (including KOL partnerships with Wenzhou Medical University Eye Hospital, Fudan University Eye Hospital, Tianjin Eye Hospital, and Peking University People's Hospital) with a nationwide distributor/dealer network for broader hospital and clinic penetration. Pricing is not publicly disclosed and is quoted case-by-case through sales representatives and distributors.

Vision X is registered as 维视艾康特(广东)医疗科技股份有限公司 (Guangdong) and operates manufacturing facilities across Shanghai (rigid lenses, headquarters), Hangzhou (diagnostic instruments), Ningbo, and Zhuhai (ocular care solutions), supported by wholly owned operating subsidiaries in each city. The company has raised multiple funding rounds from Angel through Series B+ (cumulative funding described in sources as 'exceeding 100 million RMB,' achieving unicorn status post-Series A), with investors including Sequoia Capital China (Series A lead), Sherpa Healthcare Partners, Fosun Venture Capital, Pine Venture Capital, YuanSheng Investment, Hengqin Financial Investment, and — per Crunchbase — Temasek and Lake Bleu Capital as cross-over participants. In 2023 it was designated a Shanghai Key Service Unicorn Potential Enterprise by the Shanghai Municipal Government and was named among the Top 10 Medical Device Investment Cases by Touzhong.com and the Top 50 Healthcare Investment Value Companies by CHC Medical.

Vision X firmographics

Firmographics
Name
Vision X
Legal name
维视艾康特(广东)医疗科技股份有限公司
Website
https://icomfit.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
51–100 employees
Short description
Vision X (维视艾康特) is a Shanghai-based Chinese medical device company that develops, manufactures, and sells NMPA Class III ophthalmic products — including Ortho-K lenses, domestically developed scleral lenses, myopia control spectacle lenses, optical biometers, and care solutions — serving hospitals, eye clinics, and patients across China.
Ownership category
akta.pro rank

Vision X industry classification

Industry
Product category
Ophthalmic Medical Devices
NAICS
Ophthalmic Goods Manufacturing (339115)
SIC
Ophthalmic Goods (3851)
akta.pro industry
PRIMARYHLAHAJAE
Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAHAJAD
Optical Dispensing & Eyewear Devices (Frames, Lenses, Lens Edging/Finishing Equipment)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAA
Comprehensive Eye Exams & Vision Care

Keywords

  • Ophthalmic medical devices
  • Myopia control solutions
  • Rigid contact lenses
  • Orthokeratology lenses
  • Ocular diagnostic equipment

Where Vision X is headquartered

Location

Headquarters

HQ city
Zhuhai
HQ country
China
HQ region
Asia

Offices5 records

Markets served

Vision X business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Medical Device Sales — Myopia Control Solutions: Revenue from sale of myopia control products including orthokeratology lenses and related care solutions. One-time purchase model with repeat purchase of consumables/care products.
  2. Medical Device Sales — Ophthalmic Equipment: Revenue from sale of ophthalmic diagnostic and treatment equipment to hospitals and clinics.
  3. Medical Device Sales — Ocular Surface Management: Revenue from scleral lenses and ocular surface disease management devices for irregular cornea and dry eye patients.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Vision X product offering

Product offering

Core offering

Vision X (维视艾康特) designs, manufactures, and sells ophthalmic medical devices and eye care solutions, including orthokeratology (Ortho-K) lenses, rigid gas permeable (RGP) scleral lenses, defocus spectacle lenses for myopia control, silicone hydrogel soft contact lenses, lens care solutions, and optical biometric diagnostic equipment. The company serves hospitals, eye clinics, and medical institutions in China through direct enterprise sales and a nationwide distributor network.

Product overview

Vision X (维视艾康特) offers a comprehensive portfolio of ophthalmic medical devices and eye care solutions organized into five business segments: (1) Myopia Management - including 艾康菲®角膜塑形镜 (Ortho-K lenses with AI fitting), 艾沐皓锐®离焦框架镜 (H.O.R.I. spectacle lenses), and 硅水凝胶多焦软镜; (2) Irregular Astigmatism and Ocular Surface Health - including 艾康菲®硬性巩膜接触镜 (scleral lenses, first domestically developed) and 艾康菲®硬性角膜接触镜 (RGP lenses); (3) Ophthalmic Diagnostic Instruments - including 微晓远山®眼科光学生物测量仪 with big data analytics; (4) Lens Care Solutions - including 艾康舒®无菌生理盐水 and 洗眼液; and (5) Soft Contact Lenses - including 硅水凝胶单焦软镜 and 多焦软镜 under the 沐光里 brand. The company operates as a total vision care solutions provider, from front-end diagnostic equipment through vision correction products to care solutions.

Differentiator

Problem solved

Functional benefit

Brands

  • 艾康菲 (iComfit): 硬性巩膜接触镜、角膜塑形镜、RGP等核心接触镜产品品牌
  • 艾康舒 (iComsuit)
  • 艾沐皓锐 (H.O.R.I.)
  • 微晓远山
  • 沐光里

Products and services

  • iComfit® Rigid Scleral Contact Lenses (艾康菲®硬性巩膜接触镜) Class III rigid gas permeable scleral lens with four-zone design for correcting irregular corneal astigmatism and high refractive errors in patients with keratoconus, post-LASIK ectasia, and corneal scarring. Sold to ophthalmology hospitals and clinics.
  • iComfit® Ortho-K Lenses (艾康菲®角膜塑形镜) Night-wear orthokeratology contact lenses that temporarily reshape the cornea to correct myopia, indicated for myopia up to -4.00D and astigmatism up to 1.50D. Features ACT design, SWET technology, and AI-powered corneal topography fitting for myopia control in pediatric and adolescent populations. Sold to eye hospitals and clinics.
  • H.O.R.I. Myopia Control Spectacle Lenses (艾沐皓锐®离焦框架镜) Defocus spectacle lenses for myopia control in children and teenagers, using H.O.R.I. (Hexagon Optimized Reticular Integration) technology with a 67% filling ratio grid design featuring integrated mesh, fractal boundary, and full symmetry. Sold through eye hospitals, optometry clinics, and optical retailers.
  • iComfit® RGP Contact Lenses (艾康菲®硬性角膜接触镜) Daily-wear rigid gas permeable contact lenses for correcting myopia and hyperopia, featuring smooth edge design, high oxygen permeability, and improved corneal fit. Sold to ophthalmology clinics and eye hospitals.
  • Wei Xiao Yuan Shan® Optical Biometer (微晓远山®眼科光学生物测量仪)

Companies that use Vision X

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Vision X technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Vision X partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and major.

Scale indicators2 records

Recent moves8 records

Expansion highlights6 records

Vision X competitors and assessment

Company assessment

Broad incumbents

  • Alcon: Global ophthalmic medical device and contact lens leader (Precision1, Dailies, Air Optix) and Vision X founder Li Xiaowei's prior employer. Operates broadly across the same ophthalmic device categories but at a global scale; sets the competitive benchmark for premium contact lens, surgical, and vision care products in China.
  • Bausch + Lomb: Global contact lens, lens care, and ophthalmic pharmaceutical company with established presence across soft contact lenses, RGP, and lens care solutions in China. Directly competes with Vision X across multiple product lines including the iComsuit® care solution franchise.
  • Johnson & Johnson Vision: World leader in disposable soft contact lenses (Acuvue franchise) and ortho-K (Acuvue Abiliti). Competes with Vision X in soft contact lenses, multifocal correction and myopia management categories in China.
  • CooperVision: Global contact lens manufacturer (clariti, Biofinity, MiSight myopia control lens). MiSight 1 day is a direct competitor to Vision X's pediatric myopia management soft lens strategy in China.

Direct peers

  • Euclid Systems: US-based pioneer of Ortho-K lens designs for myopia control, with established distribution in China through partnerships. Competes directly with Vision X's iComfit® Ortho-K Lenses for hospital channel adoption and clinical trial validation sites.
  • Menicon: Japan-based leader in RGP and specialty contact lenses (including ortho-K and scleral designs), with direct presence in China. Closely comparable to Vision X in scleral lens technology depth and Ortho-K offerings, and a potential international expansion benchmark.
  • Paragon Vision Sciences: Manufacturer of specialty contact lenses including CRT (Corneal Refractive Therapy) ortho-K designs and gas permeable lenses. Competes with Vision X across both Ortho-K and RGP lens categories, particularly in markets where its CRT brand has been licensed to Chinese partners.
  • Ovctek (欧普康视): China's largest domestic orthokeratology (Ortho-K) lens manufacturer and a direct competitor to Vision X in the myopia control lens segment. Both companies target the same Chinese hospital and optometry clinic channels with prescription myopia management lenses and have overlapping clinical validation strategies with leading ophthalmology hospitals.

Emerging players

  • Brighten Optix (明灏光学): Emerging Chinese player in ortho-K and defocus spectacle lenses, focused on the pediatric myopia control segment. Comparable to Vision X in scale and product overlap, and a direct domestic competitor for hospital channel partnerships.

Regional players

  • Lucid Korea: South Korea-based manufacturer of Ortho-K lenses with growing presence in Asia. Comparable to Vision X's Ortho-K technology focus and serves as a regional benchmark for scleral lens and Ortho-K product strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Vision X compliance and trust

Trust signal

Compliance5 records

Vision X financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vision X leadership team

Management profile

Number of profiles

Profiles4 records

Vision X subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Vision X funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vision X M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vision X

What does Vision X do?

Vision X (维视艾康特) designs, manufactures, and sells ophthalmic medical devices and eye care solutions, including orthokeratology (Ortho-K) lenses, rigid gas permeable (RGP) scleral lenses, defocus spectacle lenses for myopia control, silicone hydrogel soft contact lenses, lens care solutions, and optical biometric diagnostic equipment. The company serves hospitals, eye clinics, and medical institutions in China through direct enterprise sales and a nationwide distributor network.

Is Vision X a public or private company?

Vision X is a private company. It is classified as venture growth investor backed and is currently operating.

When was Vision X founded?

Vision X was founded in 2018. It employs 51 to 100 people.

Where is Vision X based?

Vision X is headquartered in Zhuhai, China, in the Asia region.

How does Vision X make money?

Three revenue lines are on record. Medical Device Sales — Myopia Control Solutions are the primary driver. The others are medical Device Sales — Ophthalmic Equipment and medical Device Sales — Ocular Surface Management.

Who are Vision X's main competitors?

Broad incumbents on record are Alcon, Bausch + Lomb, Johnson & Johnson Vision and CooperVision. Direct peers are Euclid Systems, Menicon, Paragon Vision Sciences and Ovctek (欧普康视). Brighten Optix (明灏光学) is listed as an emerging player. Lucid Korea is listed as a regional player.

Does Vision X have an API?

No public API is recorded for Vision X.

What industry is Vision X in?

Vision X's product category is Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAE, Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions), with a secondary code of HLAHAJAD, Optical Dispensing & Eyewear Devices (Frames, Lenses, Lens Edging/Finishing Equipment). Its NAICS code is 339115 and its SIC code is 3851.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales